Awe-inducing raves are linked to transformative experiences and social bonding, study finds

A study recently published in Frontiers provides new insight into the psychology of raves.

Read more
Senators Urge Biden To Grant Mass Pardon For Thousands Of Marijuana Cases

A group of senators is urging President Joe Biden to use his executive authority to grant a mass pardon for people with non-violent marijuana convictions, a first step toward righting the wrongs of prohibition.

Read more
MINDCURE Positioned For Strong Run In 2022 – CEO Q&A

MINDCURE’s President and CEO, Kelsey Ramsden updates investors on iSTRYM’s launch and rapid penetration, as well as drug development news on several fronts.

Read more
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

CYB003 is demonstrating superior treatment properties vs. an oral dosage of psilocybin.

Read more
MINDCURE’s Update Hints At Big Things To Come

As MINDCURE’s iSTRYM digital therapeutics platform rapidly gathers momentum, the company looks poised to join the emerging rally in the sector.

Read more
Novamind Reports FY2021 Financial Results and Operating Highlights

Novamind reports its full year results for fiscal 2021, including industry-leading revenue of CAD$6 million.

Read more

Read more
MINDCURE Provides Update on Studies and Clinical Trials

Mind Cure Health Inc., is pleased to provide an operational progress update on the strategic initiatives of its operating segments – MINDCURE Research and MINDCURE Technology.

Read more
Psilocybin-assisted psychotherapy might help to reduce attachment anxiety

Scientists have begun to examine whether the psychedelic drug psilocybin, the active component of “magic” mushrooms, can help people who feel insecure in their attachments to others.

Read more
Cybin Granted DEA Schedule I Manufacturing License

Cybin announces receiving its DEA Schedule I Manufacting License, necessary to work with Schedule I controlled substances in the U.S.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )